Ventricular tachycardia cost effectiveness of therapy
|
Ventricular tachycardia Microchapters |
|
Differentiating Ventricular Tachycardia from other Disorders |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Ventricular tachycardia cost effectiveness of therapy On the Web |
|
FDA on Ventricular tachycardia cost effectiveness of therapy |
|
Ventricular tachycardia cost effectiveness of therapy in the news |
|
Blogs on Ventricular tachycardia cost effectiveness of therapy |
|
to Hospitals Treating Ventricular tachycardia cost effectiveness of therapy |
|
Risk calculators and risk factors for Ventricular tachycardia cost effectiveness of therapy |
Overview
Based on a randomized clinical trial evidence, Catheter ablation of VT is unlikely to be cost-effective compared with antiarrhythmic drug (AAD) therapy. However, more detailed and better designed studies are needed to provide more informed cost-effectiveness analyses.
Cost effectiveness of therapy
Evidence from a randomized clinical trial has shown that Catheter ablation of VT is unlikely to be cost-effective compared with antiarrhythmic drug (AAD) therapy. However, better designed studies with more details and more frequent quality of life assessments are required to provide more informed cost-effectiveness analyses[1]
References
- ↑ Chen Y, Gomes M, Garcia JV, Hunter RJ, Chow AW, Dhinoja M; et al. (2020). "Cost-effectiveness of ablation of ventricular tachycardia in ischaemic cardiomyopathy: limitations in the trial evidence base". Open Heart. 7 (1): e001155. doi:10.1136/openhrt-2019-001155. PMC 6999675 Check
|pmc=value (help). PMID 32076562 Check|pmid=value (help).